Public comment periodClosed Oct 19, 2026

540/542Published
by the FDA
Read the report on the responses

Research byRecovryAI

The FDA’s 26 GenAI questions.What the public is saying.

Public feedback on the regulation of generative AI-enabled medical devices.

95 filings screened · Latest review Comments close Oct 19, 2026
FDA GenAI public feedbackAll audiences

530 responses to the FDA’s GenAI questions.

Over the first 85 days, industry contributed 286 of 530 submissions (54%), more than all other groups combined. Public / patients contributed the fewest, with 39. Comments closed on October 19.

The FDA reports 542 submissions received and 540 published as of Nov 11, 2026. Responses appear here once the FDA publishes them, and duplicates count once.

View all submissions ↗

One dot per submission. Hover or tap for details.
FDA GenAI public feedbackAll audiences

Views on the FDA’s approach to GenAI.

IndustryCliniciansPublic / patientsAcademia / other

One dot per filing; a filer who filed more than once is counted each time. The report counts each filer once.

FDA GenAI public feedbackAll audiences

The FDA GenAI questions getting the most attention.

Of the FDA’s 26 questions, these three appear most often across 530 public submissions. Counts show references, not agreement; each card also highlights leading recommendations or positions in the coded filings.

IndustryCliniciansPublic / patientsAcademia / other
Filings through Nov 10, 2026 · Responses: Sep 13 snapshot · Citing a question does not imply agreement.
Themes across the public feedbackAll audiences

Top themes shaping the FDA GenAI discussion.

A synthesis of the top emerging themes across public submissions. These themes connect several FDA questions and will evolve as new submissions are reviewed. Counts show submissions raising each theme, not agreement.

IndustryCliniciansPublic / patientsAcademia / other

FDA GenAI public feedbackAll audiences

Public feedback on all 26 FDA GenAI questions.

Explore each question and the submissions that discuss it.

IndustryCliniciansPublic / patientsAcademia / other
Demonstrating clinical competenceQ7–Q17
Filings through Nov 10, 2026 · Responses: Sep 13 snapshot · Citing a question does not imply agreement.

Who’s saying what?

All audiences shown for comparison.

Provisional mapping: industry includes startups, large companies and consultants; practitioners includes clinicians and health systems. Academia is shown separately. Filings are not a representative population survey.

The conditions matter.

How much autonomy is accepted?

Highest accepted autonomy, compared across two consequence levels.

Autonomy →

Two debates worth watching.

Two themes drawn from the FDA’s questions.
FDA GenAI public feedbackAll audiences

The public submissions behind the FDA GenAI discussion.

Browse the filings, contributors and original source documents.

Explore the 26 FDA questions

Counts show coverage among the selected audience, not agreement.

RecovryAI analysis of public regulatory submissions. Not affiliated with or endorsed by the FDA.